Data for Lenvatinib Plus Pembrolizumab and TACE in Unresectable, Nonmetastatic HCC

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss findings from LEAP-012 evaluating lenvatinib plus pembrolizumab combined with TACE in this setting. Chan outlines the biologic rationale for integrating systemic immunotherapy and antiangiogenic therapy with locoregional treatment to enhance tumor necrosis and immune activation. Cantis reviews key efficacy and safety outcomes and considers how this triplet strategy may compare with TACE alone in terms of response, progression control, and tolerability.